Compugen Ltd. is a clinical-stage cancer immunotherapy company pioneering computational target discovery powered by AI/ML. It utilizes its proprietary Unigen™ platform, a predictive AI/ML-powered computational discovery tool, to identify novel drug targets and biological pathways for developing immuno-oncology therapies. The company advances wholly owned clinical programs such as COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody in Phase 1 for platinum-resistant ovarian cancer and maintenance therapy in relapsed cases, and COM902, an Fc-reduced high-affinity anti-TIGIT antibody in Phase 1 for solid tumors. Compugen also maintains partnered programs, including bispecific antibodies with AstraZeneca featuring the TIGIT component from COM902, and GS-0321 (formerly COM503), a high-affinity anti-IL-18 binding protein antibody licensed to Gilead for Phase 1 development in advanced solid malignancies. Its pipeline extends to early-stage immuno-oncology research programs targeting new mechanisms to activate the immune system against cancer and overcome resistance. Founded in Israel and headquartered there with offices in San Francisco, California, Compugen Ltd. plays a key role in advancing differentiated antibody therapies in the oncology sector.